Latest news for Plum Acquisition (NASDAQ:PLMI) Stock

Plum Acquisition Corp I is a blank check company.

Plum Acquisition Corp. I - Class A Ordinary Share

Plum Acquisition Corp I

Needham analyst Scott Berg reiterates Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) with a Buy and maintains $55 price target.

News

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Sprout Social, Maintains $55 Price Target

Guidance

GE Vernova Raises FY24 Revenue Guidance To Towards Higher End of $34B-$35B Range vs $34.63B Est.; Raises FY24 Adjusted EBITDA Margin Guidance From Higher End of Mid-Single Digits To 5%-7%; Raises FY24 Free Cash Flow Guidance From $0.7B-$1.1B To $1.3B-$1.7B

GE Vernov (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) reported quarterly sales of $8.200 billion which missed the analyst consensus estimate of $8.259 billion by 0.71 percent.

Earnings

Earnings Misses

GE Vernov Q2 Sales $8.2B Miss $8.259B Estimate

GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) shares are trading lower today. The company revealed that EVA Air, following its recent&nbsp;order for four Boeing 787-10 Dreamliners, has also ordered <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/n39924815/eva-orders-genx-engines-to-power-boeing-787-fleet-expansion" rel="noreferrer noopener">GEnx engines for their new aircraft</a>.
Introduced in 2011, the GEnx engine family has amassed over 56 million flight hours and is GE Aerospace&#8217;s fastest-selling high-thrust engine with nearly 3,000 units in service or backlog.
GE Aerospace announced that American Airlines Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) had finalized an order for 180 CF34-8E engines and spares to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/n39905619/american-airlines-orders-180-cf34-engines-to-power-new-embraer-175-fleet" rel="noreferrer noopener">power its 90 new Embraer 175 regional jets</a>.
With over 7,500 CF34 engines in use by 900+ operators worldwide, the CF34-8E has logged over 40 million flight hours and 29 million cycles since 2004. The CF34 family, including -3, -8, and -10 models, powers over 2,500 regional aircraft.
GE Aerospace has delivered nearly 11,000 CF34 engines, boasting a 99.97% dispatch reliability rate over the past year and compatibility with approved SAF fuel blends.
Yesterday, GE Aerospace reported&nbsp;second-quarter 2024 adjusted revenue growth of 4% year-over-year to $8.22 billion, missing the <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39906980/ge-aerospace-reports-mixed-q2-results-raises-full-year-profit-and-cash-flow-guidance" rel="noreferrer noopener">consensus of $8.462 billion</a>.
The company witnessed total orders growth of 18% Y/Y to $11.2 billion, with Commercial Engines &amp; Services +38% and Defense &amp; Propulsion Technologies -25%.
Also, this week, GE Aerospace teamed up with Oak Ridge to enhance supercomputing for next-gen <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39880146/ge-aerospace-invests-in-supercomputing-talent-plans-to-hire-900-engineers" rel="noreferrer noopener">aircraft engine tech like Open Fan</a>.
The company plans to hire over 900 engineers in 2024 to drive innovation and support both current engine programs and future flight technologies.
Investors can gain exposure to the stock via IShares U.S. Aerospace &amp; Defense ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>)&nbsp;and TCW Transform Systems ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NETZ#NYSE">NETZ</a>).
Price Action: GE shares are trading lower by 0.18% at $171.69 premarket at the last check Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Large Cap

Contracts

iShares Dow Jones US Aerospace & Defense Index Fund

Engine No. 1 ETF Trust Engine No. 1 Transform Climate ETF

NETZ

GE Aerospace Wins Orders From EVA Air And American Airlines: Details

Canaccord Genuity analyst Joseph Vafi maintains Iris Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Buy and raises the price target from $12 to $15.

IREN

Canaccord Genuity Maintains Buy on Iris Energy, Raises Price Target to $15

Needham analyst John Todaro maintains Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) with a Buy and lowers the price target from $15 to $13.

RIOT

Needham Maintains Buy on Riot Platforms, Lowers Price Target to $13

TMHC

Taylor Morrison Expects Q3 Home Closings To Be Approximately 3,200, Home Closings Gross Margin To Be Around 24%

WIIM

MSGE

Madison Square Garden shares are trading higher after Goldman Sachs upgraded the stock from Neutral to Buy and raised its price target from $41 to $45.

HC Wainwright &amp; Co. analyst Yi Chen reiterates Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) with a Buy and maintains $7 price target.

ANIX

HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $7 Price Target

DA Davidson analyst Linda Bolton Weiser maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Buy and maintains $191 price target.

DA Davidson Maintains Buy on Estee Lauder Cos, Maintains $191 Price Target

Goldman Sachs analyst Mark Delaney maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Neutral and lowers the price target from $248 to $230.

TSLA

Goldman Sachs Maintains Neutral on Tesla, Lowers Price Target to $230

Taylor Morrison Home Now Expects To Deliver 12,600 - 12,800 Homes This Year (Prior View 12,500) At Home Closings Gross Margin Around 24% (Prior View 23.5% - 24.0%)

RIVN

Rivian shares are trading lower after a report indicating the company will face a trial in a Tesla trade secrets theft case.

Vertiv Holdings shares are trading higher after the company reported better-than-expected Q2 EPS and sales. Additionally, the company raised its FY24 guidance.

2024 Outlook1
Otis is revising its full year outlook:
&nbsp;
<ul>
<li>Net sales of $14.3 billion to $14.5 billion</li>
<li>Organic sales up 1% to 3%
<ul>
<li>Organic New Equipment sales down mid-single digits</li>
<li>Organic Service sales up 6% to 7%</li>
</ul>
</li>
<li>Adjusted operating profit of $2.40 billion to $2.45 billion, up $160 million to $190 million at constant currency; up $135 million to $175 million at actual currency</li>
<li>Adjusted EPS of $3.85 to $3.90, up 9% to 10%; adjusted effective tax rate of approximately 25.25%</li>
<li>Adjusted free cash flow of approximately $1.5 billion to $1.6 billion</li>
</ul>

OTIS

Otis Worldwide Revises FY2024 Adj EPS Guidance from $3.83-3.90 To $3.85-$3.90 vs $3.87 Est; Lowers FY2024 Sales Guidance from $14.50B-$14.80B To $14.30B-$14.50B vs $14.62B Est

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) with a Buy and maintains $12 price target.

EYEN

HC Wainwright & Co. Reiterates Buy on Eyenovia, Maintains $12 Price Target

GERN

Geron shares are trading lower after the company announced the departure of CCO Anil Kapur.

Taylor Morrison Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMHC#NYSE">TMHC</a>) reported quarterly earnings of $1.97 per share which beat the analyst consensus estimate of $1.90 by 3.68 percent. This is a 7.08 percent decrease over earnings of $2.12 per share from the same period last year. The company reported quarterly sales of $1.991 billion which beat the analyst consensus estimate of $1.839 billion by 8.24 percent. This is a 3.40 percent decrease over sales of $2.061 billion the same period last year.

Earnings Beats

Taylor Morrison Home Q2 2024 Adj EPS $1.97 Beats $1.90 Estimate, Sales $1.991B Beat $1.839B Estimate

GOOG

GOOGL

Alphabet shares are trading lower following Q2 earnings.

Perfect Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PERF#NYSE">PERF</a>) announced financial results for the three months ended June 30, 2024, the second quarter.
Total revenue was $13.9 million, compared to $12.7 million year ago, an increase of 9.6%. The increase was primarily due to growth in the revenue of AI- and AR-cloud solutions and mobile app subscriptions.
Gross profit was $11.0 million compared with $10.2 million in the year-ago quarter, an increase of 7.8%.
Despite the increase in gross profit, the gross margin slightly decreased to 79.3% for the second quarter, from 80.6% last year, primarily due to the increase in third-party payment processing fees paid to digital distribution partners such as Google and Apple related to the growth in its mobile app subscription revenue.
Net income was $0.8 million for Q2 compared to a net loss of $0.2 million. Adjusted net income was $1.3 million compared to adjusted net income of $0.9 million in 2023, an increase of 43.8%.
Operating cash flow was $2.0 million in the second quarter of 2024, compared to $2.6 million a decrease of 24.6%.
As of June 30, 2024, Perfect Corp held $120.8 million in cash and cash equivalents, compared to $122.0 million as of March 31, 2024.
Perfect Corp had 151 key customers as of June 30, 2024, compared with 152 as of March 31, 2024. The slight decrease in the number of key customers primarily resulted from specific brand clients&#8217; non-renewal of customer contracts due to financial pressure, among other factors.
As of June 30, 2024, Perfect Corp&#8217;s cumulative customer base included 686 brand clients, with over 774,000 digital stock-keeping units for makeup, haircare, skincare, eyewear, and jewelry products, compared to 666 brand clients and over 745,000 digital SKUs as of March 31, 2024.
Perfect Corp&#8217;s YouCam mobile beauty app active subscribers grew by 18.3% year-over-year, reaching a record high of over 919,000 active subscribers at the end of the second quarter of 2024.
Perfect Corp expects such legacy non-recurring revenue to become increasingly insignificant as it continues strengthening its market leadership in providing AI—and AR-based SaaS subscription solutions for brands and customers.
Based on the growth momentum in enterprise SaaS solution demands and YouCam mobile app subscriptions during the first half of 2024, Perfect Corp reiterates its expectation that the year-over-year growth rate of total revenue in 2024 would range from 12% to 16% compared to 2023.
Price Action: PERF shares closed higher by 1.85% at $2.20 at Tuesday.

Market-Moving Exclusives

Exclusives

PERF

EXCLUSIVE: Perfect Corp's Q2 Revenue Jumps 9.6%, YouCam App Subscribers Hit Record High

Veea to go public via business combination with Plum Acquisition Corp. I

An announcement from Plum Acquisition (PLMI) is now available. Veea Inc. has made its latest investor presentation available on its website, which ...

Plum Acquisition Unveils New Veea Investor Presentation

PLMI

Press Releases

Veea, Inc. and Plum Acquisition Corp. I Announce Letter of Intent for a Business Combination

Veea to Become Publicly Traded Company via proposed Business Combination with Plum Acquisition Corp. I

Plum Acquisition

Veea Inc. (&quot;Veea&quot; or the &quot;Company&quot;), a digital transformation company, and Plum Acquisition Corp. I (&quot;Plum&quot;, and together, the &quot;Parties&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLMI#NASDAQ">PLMI</a>), a Cayman Islands exempted company formed as a special purpose acquisition company by Ursula Burns, Kanishka Roy and Mike Dinsdale, today announced their entry into a definitive business combination agreement (the &quot;Business Combination Agreement&quot;) related to a proposed merger (such merger and related transactions, including the issuance by Plum of securities in connection therewith, collectively, the &quot;Business Combination&quot;) expected to result in Veea becoming a publicly traded company (referred to herein as the &quot;Combined Company&quot; ) whose business, after the closing (the &quot;Closing&quot;), assuming the occurrence thereof, will be the continued business of Veea.&nbsp;

IPOs

Digital Transformation Company Veea to Become Publicly Traded Company via SPAC Merger With Plum Acquisition Corp. I

Under the terms of the non-binding letter of intent, Veea and Plum would become a combined entity, with Veea&#39;s existing shareholders exchanging their shares in Veea for equity in the combined public company. Veea and Plum expect to finalize a definitive business combination agreement in the coming weeks and plan to announce additional details at that time.

Reported Earlier, Veea, A Digital Transformation Company And Plum Acquisition Corp. I Ink Letter Of Intent For A Business Combination

Sakuu To Become Publicly Traded Company Via Business Combination With Plum Acquisition I

Management

Plum Acquisition Corp. I In 8K Filing Names Kanishka Roy, Mike Dinsdale As Co-CEOs

&nbsp;

Before 10 a.m. ET on Wednesday, 49 companies set new 52-week lows.

<h2>Noteworthy Highlights:</h2>

<ul>
	<li>The largest company in terms of market cap to set a new 52-week low was China Life Insurance Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFC#NYSE">LFC</a>).</li>
	<li>Chembio Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEMI#NASDAQ">CEMI</a>) was the smallest firm on a market cap basis to set a new 52-week low.</li>
	<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTME#NASDAQ">UTME</a>) saw the most pronounced move, as shares traded down 3.31% to hit its new 52-week low.</li>
</ul>

The following stocks set new 52-week lows as of 10 a.m. ET on Wednesday:

<ul>
	<li>China Life Insurance Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFC#NYSE">LFC</a>) stock drifted down 0.75% on Wednesday morning to hit a new 52-week low of $9.25.</li>
	<li>Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) stock hit $42.02 on Wednesday morning, setting a new 52-week low for a change of down 0.26%.</li>
	<li>Playtika Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTK#NASDAQ">PLTK</a>) stock hit $22.28 on Wednesday morning, setting a new 52-week low for a change of down 0.92%.</li>
	<li>AbCellera Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCL#NASDAQ">ABCL</a>) stock set a new 52-week low of $18.92 on Wednesday, moving down 1.89%.</li>
	<li>Galapagos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPG#NASDAQ">GLPG</a>) shares fell to $67.02 on Wednesday, setting a new 52-week low with a shift of down 1.52%.</li>
	<li>Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) stock achieved a new 52-week low on Wednesday morning, hitting $62.89 and moving down 3.04%.</li>
	<li>Cal-Maine Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>) stock dropped to a yearly low on Wednesday of $34.42. Shares traded down 0.72%.</li>
	<li>Air Transport Services Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) stock achieved a new 52-week low on Wednesday morning, hitting $21.99 and moving down 1.21%.</li>
	<li>SiriusPoint (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPNT#NYSE">SPNT</a>) stock dropped to a yearly low on Wednesday of $9.80. Shares traded down 0.3%.</li>
	<li>Original BARK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BARK#NYSE">BARK</a>) stock hit a yearly low of $9.21. The stock was down 2.7% for the day.</li>
	<li>Smart Share Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) shares set a new yearly low of $5.54 this morning. The stock was down 0.89% on the session.</li>
	<li>Cloopen Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAAS#NYSE">RAAS</a>) stock set a new 52-week low of $6.93 on Wednesday, moving down 0.83%.</li>
	<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) stock hit $18.67 on Wednesday morning, setting a new 52-week low for a change of up 0.37%.</li>
	<li>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) shares set a new yearly low of $12.79 this morning. The stock was down 0.31% on the session.</li>
	<li>Vintage Wine Estates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWE#NASDAQ">VWE</a>) stock set a new 52-week low of $11.06 on Wednesday, moving up 0.9%.</li>
	<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares reached a new 52-week low of $6.60 on Wednesday morning, moving down 2.01%.</li>
	<li>Pharvaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHVS#NASDAQ">PHVS</a>) shares hit a yearly low of $15.08. The stock was up 2.26% on the session.</li>
	<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares set a new 52-week low of $14.02. The stock traded down 0.35%.</li>
	<li>Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) shares reached a new 52-week low of $11.18 on Wednesday morning, moving down 1.81%.</li>
	<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock drifted down 0.66% on Wednesday morning to hit a new 52-week low of $6.01.</li>
	<li>Plum Acquisition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLMI#NASDAQ">PLMI</a>) shares set a new 52-week low of $9.65. The stock traded up 0.52%.</li>
	<li>Neoleukin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLTX#NASDAQ">NLTX</a>) shares hit a yearly low of $9.05. The stock was down 0.43% on the session.</li>
	<li>Finserv Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSRX#NASDAQ">FSRX</a>) shares were 0.0% (flat) for the day, having made a 52-week low of $9.65.</li>
	<li>89bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETNB#NASDAQ">ETNB</a>) stock achieved a new 52-week low on Wednesday morning, hitting $16.56 and moving up 0.18%.</li>
	<li>Angion Biomedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGN#NASDAQ">ANGN</a>) shares moved up 0.75% on Wednesday to hit a new 52-week low of $11.02, drifting up 0.75%.</li>
	<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares set a new yearly low of $11.27 this morning. The stock was down 0.51% on the session.</li>
	<li>Kala Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) stock hit a yearly low of $4.62. The stock was down 2.37% for the day.</li>
	<li>Social Capital Suvretta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNAA#NASDAQ">DNAA</a>) shares reached a new 52-week low of $10.00 on Wednesday morning, moving down 0.2%.</li>
	<li>Cogent Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) stock hit a new 52-week low of $7.05. The stock was down 2.96% on the session.</li>
	<li>Terns Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) stock drifted up 1.1% on Wednesday morning to hit a new 52-week low of $10.50.</li>
	<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock achieved a new 52-week low on Wednesday morning, hitting $20.25 and moving down 1.69%.</li>
	<li>Gemini Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMTX#NASDAQ">GMTX</a>) shares hit a yearly low of $5.63. The stock was down 0.35% on the session.</li>
	<li>Lead Edge Growth Opps (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGA#NASDAQ">LEGA</a>) shares made a new 52-week low of $9.65 on Wednesday. The stock was down 0.31% for the day.</li>
	<li>Waitr Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTRH#NASDAQ">WTRH</a>) shares moved up 0.09% on Wednesday to hit a new 52-week low of $1.73, drifting up 0.09%.</li>
	<li>Miromatrix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRO#NASDAQ">MIRO</a>) stock drifted down 3.01% on Wednesday morning to hit a new 52-week low of $9.72.</li>
	<li>Surgalign Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRGA#NASDAQ">SRGA</a>) shares reached a new 52-week low of $1.27 on Wednesday morning, moving down 0.76%.</li>
	<li>Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) shares set a new yearly low of $3.76 this morning. The stock was down 1.31% on the session.</li>
	<li>NeuBase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBSE#NASDAQ">NBSE</a>) stock set a new 52-week low of $4.16 on Wednesday, moving down 1.17%.</li>
	<li>Puxin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEW#NYSE">NEW</a>) shares set a new 52-week low of $1.53. The stock traded down 2.48%.</li>
	<li>Jiuzi Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) stock dropped to a yearly low on Wednesday of $6.25. Shares traded down 2.57%.</li>
	<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) stock achieved a new 52-week low on Wednesday morning, hitting $9.00 and moving down 0.44%.</li>
	<li>Meten EdtechX Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METX#NASDAQ">METX</a>) stock hit a yearly low of $0.83. The stock was down 0.53% for the day.</li>
	<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTME#NASDAQ">UTME</a>) stock drifted down 3.31% on Wednesday morning to hit a new 52-week low of $9.60.</li>
	<li>Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) stock set a new 52-week low of $1.72 on Wednesday, moving down 2.79%.</li>
	<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) stock broke to a new 52-week low of $0.82 on Wednesday. Shares of the company traded down 0.81%.</li>
	<li>Celyad Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYAD#NASDAQ">CYAD</a>) shares set a new 52-week low of $5.05. The stock traded down 0.01%.</li>
	<li>Tian Ruixiang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) stock hit a yearly low of $5.37. The stock was down 1.92% for the day.</li>
	<li>FedNat Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNHC#NASDAQ">FNHC</a>) shares were 0.0% (flat) for the day, having made a 52-week low of $3.70.</li>
	<li>Chembio Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEMI#NASDAQ">CEMI</a>) shares fell to $2.77 on Wednesday, setting a new 52-week low with a shift of down 0.36%.</li>
</ul>

&nbsp;

Be sure to monitor Benzinga for the news traders need!

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Plum Acquisition

News

Latest news for Plum Acquisition (NASDAQ:PLMI) Stock

Tuesday, November 28, 2023

Monday, November 13, 2023

Thursday, March 02, 2023

Monday, January 31, 2022

Wednesday, July 07, 2021